GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

  • September 2020 •
  • 224 pages •
  • Report ID: 5961988 •
  • Format: PDF
KEY FINDINGS
The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% during the forecast period, 2019-2028. The factors propelling the growth of the market are estimated to be the rising usage of minimally invasive processes, increasing research & development expenditure, and the growing prevalence of kidney cancer cases.

MARKET INSIGHTS
There is an increasing prevalence of cancer, along with the rising adoption of early diagnosis.Some estimations suggest that there will be a 22% increase in kidney cases across the globe in 2020.

It is necessary to diagnose and treat kidney cancer at the earliest, since it is associated with several comorbidities. Recent advancements like the liquid biopsy technique are projected to result in healthy demand for kidney cancer diagnosis.
There is an emphasis on using minimally-invasive techniques in surgical procedures.There has been an increase in the use of the minimally-invasive catheter-based endovascular procedure to regulate hypertension.

This has resulted in the growing adoption of kidney cancer treatment devices.These devices reduce cardiometabolic risks.

They also aid in minimizing hospital stay, since the procedure and the necessary processes do not take more than six hours.This restricts direct and indirect hospitalization costs.

Thus, rising minimally-invasive processes drive market growth. However, the high costs associated with the treatment and diagnosis, are projected to restrain the market growth.

REGIONAL INSIGHTS
The analysis of the geographical division of the global kidney cancer therapeutics and diagnostics market includes the assessment of Asia Pacific, Europe, North America, and the rest of the world.North America dominated the global market in 2019.

The well-developed healthcare infrastructure and the presence of major companies are influencing the market growth prospects of the region.

COMPETITIVE INSIGHTS
As per estimations, there will be intense competition between the well-established cancer therapeutics manufacturers. Some of the established players in the market include Bayer AG, Amgen Inc, Abbott Laboratories, Becton, Dickinson and Company (BD), etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. ABBOTT LABORATORIES
2. AMGEN INC
3. BAYER AG
4. BECTON, DICKINSON AND COMPANY (BD)
5. BRISTOL-MYERS SQUIBB COMPANY
6. EXELIXIS
7. F. HOFFMANN-LA ROCHE
8. MERCK & CO INC
9. MERCK KGAA
10. NOVARTIS INTERNATIONAL AG
11. NXSTAGE MEDICAL INC
12. PFIZER INC
13. SEATTLE GENETIC